A Non-inferiority Trial Of Cytisine Versus Varenicline For Smoking Cessation.
Funder
National Health and Medical Research Council
Funding Amount
$1,885,813.00
Summary
Long-term quit rates via existing behavioural and pharmacological approaches to smoking cessation remain low and there is a need for further evidence-based treatments to complement standard treatment. We will conduct a large-scale trial to demonstrate the cost-effectiveness of cytisine compared to existing varenicline treatment. The findings will have direct health care system implications and cytisine, if effective, has the potential to save millions of lives globally.